Several biomarkers obtained through non-invasive means could help to predict the development of non-alcoholic fatty liver disease in patients living with HIV (PWH), according to recent research.
The FibroScan-AST (FAST) score has been shown to be effective for the risk assessment of non-alcoholic hepatic steatosis (NASH) in patients without HIV, but its effectiveness in HIV+ patients is currently...
In his session at CROI 2019, Jay Gobler from Merck & Co presented the preliminary data from his phase 2 clinical trial of MK-8591 for the treatment of HIV-1 infection.
By analyzing the association between baseline 10-year cardiovascular risk scores and NPZ-4, researchers determined whether 2 common CVD risk scores could predict later cognitive function. The findings were...
A new study presented at CROI 2019 explored whether switching to monthly long-acting CAB+RPV is noninferior to continuing current 3-drug oral ART in adults with virologically suppressed HIV-1 infection. ...
Certain biomarkers could be used to identify people living with HIV who are at increased risk of developing non-alcoholic fatty liver disease, according to recent research.
Alveolar macrophages play an important role in host defense against pathogenic microorganisms and tissue remodeling. In their study, Dr Charles P. Neff and colleagues investigated the effect of HIV and...
At CROI 2019, Dr Rosie Mngqibisa presented results from her study that evaluated whether concurrent use of rifampicin and efavirenz impacts the efficacy of DMPA, a commonly used contraceptive.
